Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims
This article was originally published in The Tan Sheet
Executive Summary
The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.
You may also be interested in...
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Perrigo launches store brand Mucinex D, containing guaifenesin and PSE, manufactured by Allergan, but also suspends marketing its own guaifenesin product due to problems with an excipient used in the formula.
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Perrigo launches store brand Mucinex D, containing guaifenesin and PSE, manufactured by Allergan, but also suspends marketing its own guaifenesin product due to problems with an excipient used in the formula.
With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
Perrigo hopes to ship store-brand Mucinex expectorant products in time for the next cough and cold season, but analysts are skeptical with several targets for the launch missed already. However, the firm can drive growth through mergers and acquisitions and Rx-to-OTC growth opportunities.